227 related articles for article (PubMed ID: 25140563)
1. PET response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90Yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma.
Camacho JC; Kokabi N; Xing M; Schuster DM; Kim HS
Clin Nucl Med; 2014 Nov; 39(11):944-50. PubMed ID: 25140563
[TBL] [Abstract][Full Text] [Related]
2. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
3. Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver.
Edalat F; Camacho JC; Kokabi N; Kendi AT; Galt JR; Kim HS
Clin Nucl Med; 2016 Feb; 41(2):e76-81. PubMed ID: 26447380
[TBL] [Abstract][Full Text] [Related]
4. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.
Haug AR; Heinemann V; Bruns CJ; Hoffmann R; Jakobs T; Bartenstein P; Hacker M
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1037-45. PubMed ID: 21308371
[TBL] [Abstract][Full Text] [Related]
6. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma.
Filippi L; Pelle G; Cianni R; Scopinaro F; Bagni O
Nucl Med Biol; 2015 Jan; 42(1):59-64. PubMed ID: 25213104
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization.
Filippi L; Di Costanzo GG; Tortora R; Pelle G; Saltarelli A; Marino Marsilia G; Cianni R; Schillaci O; Bagni O
Nucl Med Commun; 2020 Jan; 41(1):78-86. PubMed ID: 31800510
[TBL] [Abstract][Full Text] [Related]
9. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
[TBL] [Abstract][Full Text] [Related]
10. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
Mouli S; Memon K; Baker T; Benson AB; Mulcahy MF; Gupta R; Ryu RK; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2013 Aug; 24(8):1227-34. PubMed ID: 23602420
[TBL] [Abstract][Full Text] [Related]
11. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
[TBL] [Abstract][Full Text] [Related]
12. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment.
Rayar M; Sulpice L; Edeline J; Garin E; Levi Sandri GB; Meunier B; Boucher E; Boudjema K
Ann Surg Oncol; 2015 Sep; 22(9):3102-8. PubMed ID: 25623598
[TBL] [Abstract][Full Text] [Related]
13. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.
Al-Adra DP; Gill RS; Axford SJ; Shi X; Kneteman N; Liau SS
Eur J Surg Oncol; 2015 Jan; 41(1):120-7. PubMed ID: 25449754
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients.
Reimer P; Virarkar MK; Binnenhei M; Justinger M; Schön MR; Tatsch K
Cardiovasc Intervent Radiol; 2018 May; 41(5):744-752. PubMed ID: 29344713
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma.
Boehm LM; Jayakrishnan TT; Miura JT; Zacharias AJ; Johnston FM; Turaga KK; Gamblin TC
J Surg Oncol; 2015 Feb; 111(2):213-20. PubMed ID: 25176325
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT).
Beuzit L; Edeline J; Brun V; Ronot M; Guillygomarc'h A; Boudjema K; Gandon Y; Garin E; Rolland Y
Eur J Radiol; 2016 Aug; 85(8):1445-52. PubMed ID: 27423686
[TBL] [Abstract][Full Text] [Related]
17. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.
Saxena A; Bester L; Chua TC; Chu FC; Morris DL
Ann Surg Oncol; 2010 Feb; 17(2):484-91. PubMed ID: 19876691
[TBL] [Abstract][Full Text] [Related]
19. Repeated Treatment with
Filippi L; Di Costanzo GG; Tortora R; Pelle G; Cianni R; Schillaci O; Bagni O
Cancer Biother Radiopharm; 2019 May; 34(4):231-237. PubMed ID: 30758985
[No Abstract] [Full Text] [Related]
20. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.
Hyder O; Marsh JW; Salem R; Petre EN; Kalva S; Liapi E; Cosgrove D; Neal D; Kamel I; Zhu AX; Sofocleous CT; Geschwind JF; Pawlik TM
Ann Surg Oncol; 2013 Nov; 20(12):3779-86. PubMed ID: 23846786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
